Search Results
Nov 14, 2025, 02:55 ET Diamyd Medical's pivotal Phase 3 Type 1 Diabetes trial clears last safety review ahead of early readout in March 2026
antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production specifically for individuals carrying a HLA DR3-DQ2 gene. Diamyd® has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage
More news about: Diamyd Medical AB
Nov 14, 2025, 02:52 ET Diamyd Medical's pivotal Phase 3 Type 1 Diabetes trial clears last safety review ahead of early readout in March 2026
antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production specifically for individuals carrying a HLA DR3-DQ2 gene. Diamyd® has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage
More news about: Diamyd Medical AB
Nov 13, 2025, 18:51 ET Leqembi® approved for IV maintenance treatment in the United Kingdom
involved in the metabolism of lipid in humans. It is implicated in AD. People with only one (heterozygous) or no copy (non-carriers) of the ApoE ε4 gene are less likely to experience ARIA than people with two ApoE ε4 copies (homozygous). [2] Alzheimer's
More news about: BioArctic
Nov 13, 2025, 18:50 ET Leqembi® approved for IV maintenance treatment in the United Kingdom
involved in the metabolism of lipid in humans. It is implicated in AD. People with only one (heterozygous) or no copy (non-carriers) of the ApoE ε4 gene are less likely to experience ARIA than people with two ApoE ε4 copies (homozygous). [2] Alzheimer's
More news about: BioArctic
Nov 13, 2025, 15:08 ET Pivot Bio Expands Weatherproof Nitrogen Portfolio with New Dry Planter Box Treatments for Corn and Cotton
G3 Dry for corn and Pivot Bio CERT-N™ Dry for cotton, giving farmers another convenient, reliable way to apply the company's exclusive, proprietary gene-edited microbes at planting.
More news about: Pivot Bio, Inc
Nov 13, 2025, 11:07 ET Immune Reactions Found Behind Human Rejection of Transplanted Pig Kidneys
greater detail, says Montgomery, who is a co-author. The research team conducted a multi-omics analysis, which integrates information about gene function, gene expression (activity level), and proteins, as well as other data, to gain a holistic understanding of complex mechanisms at work in the immune
More news about: NYU Grossman School of Medicine and NYU Langone Health
Nov 13, 2025, 10:15 ET Next Generation Sequencing (NGS) Market Poised to Hit $42.25 Billion by 2033: Key Drivers Behind the Surge - Latest Study by Grand View Research, Inc.
PGT Newborn Genetic Screening Single Gene Analysis HLA Typing/Immune System Monitoring Metagenomics, Epidemiology
More news about: Grand View Research, Inc.
Nov 13, 2025, 10:10 ET Shally Steckerl Joins ProvenBase Advisory Board as AI-Powered Deep Search Platform Signs Major Corporate Clients
couldn't." The platform's proprietary AI technology goes beyond keyword matching to understand contextual expertise. A search for "CRISPR gene editing expertise" successfully identifies candidates who describe their work as "genome modification using Cas9 proteins" or "targeted DNA sequence
More news about: ProvenBase
Nov 13, 2025, 10:04 ET NNT 2025 Celebrates 30 Years of Nanoimprint -- One of the Most Transformative Technologies of the 21st Century
consumer electronics (augmented-reality (AR) and virtual-reality (VR) goggles, smart glasses, displays, and smartphones); biotechnology and life sciences (gene sequencing, biosensing, biomedical, and pharmaceutical applications); photonics and optical communications (LEDs, lasers, lenses, modulators, meta-optics,
More news about: NNT Conference
Nov 13, 2025, 10:03 ET GB Connections Appoints Cody DeHart Vice President of Engineering, Building on Its Legacy of Quality and Innovation
appointment continues GB Connections' leadership evolution which began with the arrival of President and CEO, Robert L. Kovar in June 2024, and coincides with Gene Mannella, P.E., transitioning into an advisory role as Chairman and Executive Technology officer after 38 years of dedicated service. His leadership
More news about: GB Connections LLC
Nov 13, 2025, 09:00 ET Foundation Fighting Blindness Provides Public Access to Data From Its RUSH2A Natural History Study
de-identified four-year data from individuals participating in RUSH2A, an ongoing natural history study for people with mutations in the USH2A gene causing Usher syndrome type 2A or non-syndromic retinitis pigmentosa (RP). The goal of RUSH2A and other natural history studies sponsored by the Foundation
More news about: Foundation Fighting Blindness
Nov 13, 2025, 07:00 ET Neurvati Neurosciences Appoints Carlos Martin as Chief Commercial Officer
such as gene therapy, radiopharma, oncology, cardiology, and rare diseases. Martin most recently served as Chief Commercial Officer at Rocket Pharmaceuticals, where he oversaw the company's transition from a clinical-stage biotech to a commercial-ready organization in gene therapies.
More news about: Neurvati Neurosciences
Nov 13, 2025, 07:00 ET Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good
therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Headquartered in Bridgewater,
More news about: Insmed Incorporated
Nov 13, 2025, 05:00 ET Best Biological Age Test (2025): TruDiagnostic Recognized for Precision Health Insights by Expert Consumers
The TruAge test captures this difference by measuring DNA methylation, a process in which chemical markers attach to DNA and regulate gene expression. These epigenetic changes are influenced by daily behaviors such as diet, exercise, and sleep, making them reliable indicators of how lifestyle
More news about: ExpertConsumers.org
Nov 13, 2025, 03:30 ET Blue Cell Therapeutics appoints leading cell therapy executive Miguel Forte MD, PhD, to its Board of Directors
Miguel Forte, current President of the International Society for Cell & Gene Therapy (ISCT), joins Blue Cell as a Non-Executive Director Highly experienced
More news about: Blue Cell Therapeutics
Nov 12, 2025, 21:55 ET Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
ELVN-001 is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML).
More news about: Enliven Therapeutics, Inc.
Nov 12, 2025, 10:55 ET AgroNetica: Developing The World's First Super-Cacao Varieties That Are Drought Resistant, Mechanized Harvest Ready, No Heavy Metal Uptake and Caffeine Free.
These conditions have driven the steepest price increases for cacao in recorded history, destabilising the $40 billion cacao bean market. AgroNetica is gene-editing new cacao trees for drought resistance and high-yield growth, which will produce more beans per hectare while preserving farmer income.
More news about: AgroNetica
Nov 12, 2025, 08:00 ET Genezen Announces Manufacturing Partnership with Humane Genomics to Advance Oncolytic Virus Therapy for Pediatric Liver Cancer
Genezen Genezen is a best-in-class gene therapy CDMO with over a decade of experience and state-of-the-art viral vector manufacturing facilities. From concept to commercial scale, Genezen partners with innovators to deliver life-saving gene and cell therapies worldwide. Learn more at
More news about: Genezen
Nov 12, 2025, 07:01 ET CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
an animal model of PAH, CM5480 restored or improved multiple disease-affected pathways and functions—including heart contraction and cardiac output, gene expression profiles, DNA repair, and metabolism. Treatment with CM5480 also significantly reduced right ventricular dysfunction (RVD) both as a monotherapy
More news about: CalciMedica, Inc.
Nov 12, 2025, 07:00 ET CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension
pathways and functions that become dysregulated in animals with PAH were restored or improved. These included heart contraction and cardiac output, gene expression profiles impacted by the disease, DNA repair, and metabolic pathways. Dual therapies combining CM5480 with either ambrisentan or sildenafil
More news about: CalciMedica, Inc.
Nov 11, 2025, 13:53 ET Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti® and Rexulti® driven by additional investments
1 CGRP: Calcitonin gene-related peptide. 2 Two phase III clinical studies completed, supporting registration in Asia, including China and Japan: SUNRISE,
More news about: H. Lundbeck A/S
Nov 11, 2025, 13:38 ET Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti® and Rexulti® driven by additional investments
1 CGRP: Calcitonin gene-related peptide. 2 Two phase III clinical studies completed, supporting registration in Asia, including China and Japan: SUNRISE,
More news about: H. Lundbeck A/S
Nov 11, 2025, 10:36 ET Cold Storage Market Worth USD 198 Billion by 2030, Led by APAC and Automation Trends, Says Mordor Intelligence
and space pressures. While frozen units remain essential, demand for ultra-low and cryogenic environments is rising alongside advancements in cell and gene therapies.
More news about: Mordor Intelligence Private Limited
Nov 11, 2025, 10:30 ET Wastewater Surveillance Market worth $1.22 billion by 2030 with 6.7% CAGR | MarketsandMarkets™
driven by increasing demand for targeted and multiplex pathogen detection in wastewater. This segment includes viral and bacterial detection kits, AMR gene panels, and pharmaceutical residue testing solutions. As wastewater surveillance expands beyond COVID-19 to monitor pathogens like influenza, norovirus,
More news about: MarketsandMarkets
Nov 11, 2025, 10:13 ET Announcing the 2026 Franklin Institute Award Laureates
Inventor David R. Liu, Ph.D., to receive the Bower Award and Prize for Achievement in Science for his groundbreaking work in gene editing to correct disease-causing "misspellings" in DNA PHILADELPHIA,
More news about: The Franklin Institute